Novelion Therapeutics Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2018. For the quarter, the company reported net revenue of $27,484,000 compared to $29,984,000 a year ago. Loss from operations was $21,476,000 compared to $21,663,000 a year ago. Loss before provision for income taxes was $32,669,000 compared to $30,823,000 a year ago. Net loss was $32,828,000 compared to $30,962,000 a year ago. Net loss per common share—basic and diluted was $1.76 compared to $1.67 a year ago. Non-GAAP net loss was $13,534,000 compared to $8,687,000 a year ago. Non-GAAP net loss per common share – basic and diluted was $0.72 compared to $0.47 a year ago.